AbbVievsMinerva Neurosciences

ABBV and NERV stock compared: price, dividend, valuation and results, from SEC filings.

NERV

Minerva Neurosciences, Inc

$2.00

Value $100M

-5.66%
NERV's page

AbbVie (ABBV) has a market value of $506B and Minerva Neurosciences (NERV) $100M. Over the last year, with dividends, ABBV moved +26.6% and NERV -53.5%. Dividend yield: ABBV 2.42%, NERV none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$506B

    NERV$100M

    ABBV is 5,077 times NERV

  • Revenue, 12 months

    ABBV$66.0B

    NERV–

  • Net income, 12 months

    ABBV$10.3B

    NERV-$291M

  • Operating margin

    ABBV32.2%

    NERV–

  • ROIC

    ABBV25.7%

    NERV–

  • P/E

    ABBV49.2

    NERV–

  • Dividend yield

    ABBV2.4%

    NERV0.0%

    2.4 points apart

  • 5-year return

    ABBV+194.4%

    NERV-77.7%

    272.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+194.4%

NERV-77.7%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsNERVWith dividends
1 year since November 19, 2025+26.6%Price +22.9%-53.5%Price -53.5%
3 years since November 20, 2023+128.8%+31.8% a yearPrice +106.9%-59.5%-26.0% a yearPrice -59.5%
5 years since November 19, 2021+194.4%+24.1% a yearPrice +146.2%-77.7%-25.9% a yearPrice -77.7%
10 years since November 22, 2016+630.1%+22.0% a yearPrice +385.7%-98.2%-33.0% a yearPrice -98.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieNERVMinerva Neurosciences

Valuation

ABBVNERV
Valuation
Price$286.20$2.00
Market value$506B$100M
Enterprise value (EV)$576B–
P/E49.2–
P/E, 5-year median57.0–
P/B––
EV/EBIT27.1–
Free cash flow yield3.7%–

Results and growth

ABBVNERV
Results and growth
Revenue, 12 months$66.0B–
Net income, 12 months$10.3B-$291M
Free cash flow, 12 months$18.9B-$31M
Earnings per share, 12 months$5.81-$36.57
Revenue growth, year on year8.6%–
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVNERV
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%–
Net margin15.7%–
ROIC25.7%–
ROE––

Balance sheet

ABBVNERV
Balance sheet
Cash$10.8B$77M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVNERV
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or NERV

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Minerva Neurosciences?

By market value, AbbVie ($506B) is about 5,077.2 times Minerva Neurosciences ($100M), at today's prices.

How did ABBV and NERV stock do over the last 10 years?

Since November 22, 2016, ABBV's price moved +385.7% and NERV's -98.2%. With dividends: ABBV +630.1% (+22.0% a year), NERV -98.2% (-33.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or NERV?

The dividend yield at today's price is 2.42% for AbbVie and none for Minerva Neurosciences. Over the last twelve months they paid $6.92 and – per share.

Which is the better investment, AbbVie or Minerva Neurosciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.